Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 3/20 | 0.69 |
| ▸ | NCF1 | P14598 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | LGMN | Q99538 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.45 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.45 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.45 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27662780 | 0.87 | AGXT (0.56) | AGXTNCF1LMNASIGMAR1ADRA2C | |
| SCHEMBL13725027 | 0.87 | AGXT (0.66) | AGXTNCF1LMNAKMOKLKB1 | |
| Trifluoroacetic Acid SCHEMBL3460138 | 0.86 | L3MBTL1 (0.58) | AGXTNCF1LMNAKMOKLKB1 | |
| SCHEMBL3722035 | 0.84 | AOC3 (0.62) | AGXTNCF1LMNAADRA2AADRA2B | |
| SCHEMBL109316 | 0.84 | AGXT (0.67) | AGXTNCF1KLKB1KLK1PRMT6 | |
| SCHEMBL39888 | 0.83 | LMNA (0.52) | AGXTNCF1LMNALGMNAOC3 | |
| SCHEMBL671148 | 0.83 | AGXT (0.65) | AGXTLMNAKMOADRA2AADRA2B | |
| SCHEMBL22964326 | 0.83 | AGXT (0.65) | AGXTLMNAKMOADRA2AADRA2B | |
| SCHEMBL9302706 | 0.83 | AGXT (0.65) | AGXTLMNAKMOADRA2AADRA2B | |
| SCHEMBL4507051 | 0.83 | AGXT (0.65) | AGXTLMNAKMOADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023021498-A1 | FUSED AZOLE AND FURAN BASED NUCLEOSIDE ANALOGS AND USES THEREOF | MOYA BIO LTD. (IL) | 2023-02-23 | — | — | WO | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| EP-1307447-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | AGXT 1014/4885NCF1 716/4885LMNA 873/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | AGXT 1014/4885NCF1 716/4885LMNA 873/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | AGXT 3804/4885NCF1 1648/4885LMNA 2251/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | AGXT 3804/4885NCF1 1648/4885LMNA 2251/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | AGXT 4749/4885NCF1 591/4885LMNA 1511/4885 |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | AGXT 1764/4885NCF1 1919/4885LMNA 1249/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | AGXT 4749/4885NCF1 824/4885LMNA 1556/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | AGXT 1879/4885NCF1 1665/4885LMNA 1890/4885 |
| US-10882851-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR5A2 | AGXT 3910/4885NCF1 1388/4885LMNA 2425/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | AGXT 4328/4885NCF1 3723/4885LMNA 232/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | AGXT 3237/4885NCF1 707/4885LMNA 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.